Celera Corporation

The Brigham and Women's Hospital, Inc.

Quest Diagnostics Investments, Inc.

Applera Corporation

The University of Texas System

Dov Shiffman

James J Devlin

Paul M Ridker

Michael McPhaul

Carmen Tong

Daniel Chasman

Judy Z Louie

Eric Boerwinkle

David Ross

Michele Cargill

May Luke

Paul Ridker

Michael J McPhaul

Michael J Mcphaul

Methods are described for diagnosing or prognosing insulin resistance in diabetic and pre-diabetic patients, the method comprising determining the amount of insulin and C-peptide in a sample. Provided herein are mass spectrometric methods for detecting and quantifying insulin and C-peptide in a biological sample utilizing enrichment and/or purification methods coupled with tandem mass spectrometric or high resolution/high accuracy mass spectrometric techniques.

Methods for quantitation of insulin and C-peptide

The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment, particularly for reducing the risk of cardiovascular disease, especially coronary heart disease (such as myocardial infarction) and stroke. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents and kits for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents and kits for their detection.

Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof

This invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid.

Polymorphism in the Apo(a) gene predict responsiveness to acetylsalicylic acid treatment

The present invention provides compositions and methods based on genetic polymorphisms that are associated with cardiovascular diseases, particularly coronary heart disease (especially myocardial infarction) or hypertension. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.

Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof

The present invention is based on the discovery of genetic polymorphisms that are associated with coronary heart disease and in particular stenosis and MI and response to drug treatment. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.

Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof

Growing community of inventors

Palo Alto, CA, United States of America

Dov Shiffman